Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography

By J. Rudd, E. Warburton, T. Fryer, H. Jones, John C. Clark, N. Antoun, P. Johnström, A. Davenport, P. Kirkpatrick, B. Arch and 2 more. Circulation, 2002

1,257 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Immunology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/04ac475835fc7f9df8204276f4a12b41f7d5a55f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Richard Frank
2. H. Nakaura
3. D. Vermylen
4. K. Furie
5. G. Bashian
6. T. Brady
7. Richard Hargreaves
8. J. Muller

Citations in the corpus

• Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. (2006, background): “This is consistent with revious studies showing that the co-registered (18)FDGET with CT (5,6) or high-resolution magnetic resonance maging (MRI) (14) improved the accuracy of the diagnosis f plaque inflammation.”
• In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. (2006, methodology): “Furthermore, Rudd et al. (10,11) demonstrated increased carotid uptake of FDG in patients with evidence of a recent ischemic cerebrovascular event.”
• Clinical biomarkers in drug discovery and development (2003, background): “and fluorodeoxyglucose positron emission tomography ( 18 FDG-PET”